{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:48:50Z","timestamp":1793821730876,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Migraine is one of the main causes of disability worldwide. Anti-CGRP monoclonal antibodies (MAbs) have proven to be safe and efficacious as preventive migraine treatments. However, their use is restricted in many countries due to their apparently high cost. Cost-benefit studies are needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To study the cost-benefit of anti-CGRP MAbs in working-age patients with migraine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a prospective cohort study of consecutive migraine patients treated with anti-CGRP MAbs (erenumab, fremanezumab and galcanezumab) following National reimbursement policy in a specialized headache clinic. Migraine characteristics and the work impact scale (WPAI) were compared between baseline (M0) and after 3 (M3) and 6 months (M6) of treatment. Using WPAI and the municipal average hourly wage, we calculated indirect costs (absenteeism and presenteeism) at each time point. Direct costs (emergency visits, acute medication use) were also analysed. A cost-benefit study was performed considering the different costs and savings of treating with MAbs. Based on these data an annual projection was conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From 256 treated working-age patients, 148 were employed (89.2% women; mean age 48.0\u2009\u00b1\u20098.5 years), of which 41.2% (61\/148) were responders (&gt;\u200950% reduction in monthly headache days (MHD)). Statistically significant reductions between M0 and M3\/M6 were found in absenteeism (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and presenteeism (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Average savings in indirect costs per patient at M3 were absenteeism 105.4 euros\/month and presenteeism 394.3 euros\/month, similar for M6. Considering the monthly cost of anti-CGRP MAbs, the cost-benefit analysis showed savings of 159.8 euros per patient at M3, with an annual projected savings of 639.2 euros\/patient. Both responders and partial responders (30\u201350% reduction in MHD) presented a positive cost-benefit balance. The overall savings of the cohort at M3\/M6 compensated the negative cost-benefit balance for non-responders (&lt;\u200930% reduction in MHD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Anti-CGRP MAbs have a positive impact in the workforce significantly reducing absenteeism and presenteeism. In Spain, this benefit overcomes the expenses derived from their use already at 3 months and is potentially sustainable at longer term; also in patients who are only partial responders, prompting reconsideration of current reimbursement criteria and motivating the extension of similar cost-benefit studies in other countries.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01727-0","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T09:02:23Z","timestamp":1707728543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Early and annual projected savings from anti-CGRP monoclonal antibodies in migraine prevention: a cost-benefit analysis in the working-age population"],"prefix":"10.1186","volume":"25","author":[{"given":"Carlos","family":"Lazaro-Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Rosell-Mirmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor J","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Torres-Ferrus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"issue":"10258","key":"1727_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"C Abbafati","year":"2020","unstructured":"Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A (2020) Abdollahi M et al Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204\u20131222. http:\/\/www.thelancet.com\/article\/S0140673620309259\/fulltext.. Cited 2023 Apr 2.","journal-title":"Lancet"},{"key":"1727_CR2","doi-asserted-by":"crossref","unstructured":"Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z Migraine is first cause of disability in under 50s: will health politicians now take notice? ; https:\/\/doi.org\/10.1186\/s10194-018-0846-2. Cited 2023 Apr 2.","DOI":"10.1186\/s10194-018-0846-2"},{"issue":"5","key":"1727_CR3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z et al (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19(5):703\u2013711","journal-title":"Eur J Neurol"},{"issue":"5","key":"1727_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/head.13275","volume":"58","author":"M Bonafede","year":"2018","unstructured":"Bonafede M, Sapra S, Shah N, Tepper S, Cappell K, Desai P (2018) Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States. Headache. 58(5):700\u201314.\u00a0Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29446063\/. Cited 2023 Apr 2.","journal-title":"Headache."},{"key":"1727_CR5","doi-asserted-by":"crossref","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478\u201388.\u00a0Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/25164920\/. Cited 2023 Apr 2.","DOI":"10.1177\/0333102414547138"},{"key":"1727_CR6","doi-asserted-by":"crossref","unstructured":"Ford JH, Schroeder K, Nyhuis AW, Foster SA (2019) Aurora SK Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs. J Manag Care Spec Pharm. 25(1):46-55B.\u00a0Available from:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/30044691\/. Cited 2023 Apr 2.","DOI":"10.18553\/jmcp.2018.18058"},{"key":"1727_CR7","unstructured":"Santos Lasaosa S, Pozo Rosich P (2020) In: Gonz\u00e1lez Oria C (ed) Manual de Pr\u00e1ctica Cl\u00ednica en Cefaleas. Belv\u00eds Nieto R, Latorre Gonz\u00e1lez G. Ediciones SEN"},{"issue":"1","key":"1727_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain 23(1):67","journal-title":"J Headache Pain"},{"issue":"7","key":"1727_CR9","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1177\/0333102421989601","volume":"41","author":"K Drellia","year":"2021","unstructured":"Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD (2021) Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41(7):851\u2013864","journal-title":"Cephalalgia"},{"issue":"10","key":"1727_CR10","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268(10):3789\u20133798","journal-title":"J Neurol"},{"issue":"2","key":"1727_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J (2022) Wen S et al Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42(2):108\u2013118. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34743579\/. Cited 2023 Apr 2","journal-title":"Cephalalgia"},{"key":"1727_CR12","unstructured":"Ministerio de sanidad de Espa\u00f1a (2023) Acuerdos de la comisi\u00f3n interministerial de precios de los medicamentos."},{"key":"1727_CR13","doi-asserted-by":"crossref","unstructured":"Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G et al Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30276500\/. Cited 2023 Aug 15.","DOI":"10.1186\/s10194-018-0923-6"},{"issue":"8","key":"1727_CR14","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/jnnp-2018-320242","volume":"90","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM (2019) Zhang Q et al Research paper: Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry 90(8):939. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6691875\/. Cited 2023 Aug 15","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1727_CR15","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia (2018); 38(1):1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"1727_CR16","doi-asserted-by":"crossref","unstructured":"Varela N, Guill\u00e9n-Grima F, P\u00e9rez-Cajaraville JJ, P\u00e9rez-Hern\u00e1ndez C, Monedero P Valoraci\u00f3n de la repercusi\u00f3n del dolor sobre la productividad laboral: validaci\u00f3n del cuestionario WPAI:Pain. An Sist Sanit Navar. 2016 ;39(1):77\u201385. Available from: https:\/\/scielo.isciii.es\/scielo.php?script=sci_arttext &pid=S1137-66272016000100009&lng=es&nrm=iso&tlng=es. Cited 2023 Apr 2.","DOI":"10.23938\/S1137-6627\/2016000100009"},{"key":"1727_CR17","unstructured":"de Salut D ORDRE SLT\/71\/2020, de 2 de juny, per la qual es regulen els sup\u00f2sits i. 2020 ; Available from: https:\/\/www.gencat.cat\/dogc. Cited 2023 Apr 2."},{"key":"1727_CR18","unstructured":"Ministerio de Sanidad de Espa\u00f1a (2023) Listado de agrupaciones homog\u00e9neas de medicamentos y precios menores - Octubre 2023."},{"key":"1727_CR19","unstructured":"Generalitat de (2020) Catalunya. ORDRE SLT\/71\/2020, de 2 de juny, per la qual es regulen els sup\u00f2sits i conceptes facturables i s\u2019aproven els preus p\u00fablics corresponents als serveis que presta l\u2019Institut Catal\u00e0 de la Salut."},{"key":"1727_CR20","unstructured":"Institut d\u2019Estad\u00edstica de catalunya. https:\/\/www.idescat.cat\/indicadors\/?id=anuals&n=10402. 2023. Salari brut anual i guany per hora. Per sexe i sectors d\u2019activitat."},{"issue":"3","key":"1727_CR21","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s00415-021-10715-2","volume":"269","author":"E Caronna","year":"2022","unstructured":"Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M (2022) Pozo-Rosich P Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability. J Neurol 269(3):1456\u20131462. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34282471\/. Cited 2023 Apr 2.","journal-title":"J Neurol"},{"issue":"1","key":"1727_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s10194-022-01536-3","volume":"24","author":"E Troy","year":"2023","unstructured":"Troy E, Shrukalla AA, Buture A, Conaty K, Macken E, Lonergan R et al (2023) Medium-term real-world data for erenumab in 177 treatment resistant or difficult to treat chronic migraine patients: persistence and patient reported outcome measures after 17\u201330 months. J Headache Pain 24(1):5. https:\/\/doi.org\/10.1186\/s10194-022-01536-3.","journal-title":"J Headache Pain"},{"issue":"1","key":"1727_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. Journal of Headache and Pain 23(1):1\u201317. Available from: https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-022-01402-2. Cited 2023 Apr 2","journal-title":"Journal of Headache and Pain"},{"key":"1727_CR24","doi-asserted-by":"publisher","first-page":"100408","DOI":"10.1016\/j.ensci.2022.100408","volume":"27","author":"O de Begasse Dhaem","year":"2022","unstructured":"de Begasse Dhaem O, Sakai F (2022) Migraine in the workplace. eNeurologicalSci 27:100408","journal-title":"eNeurologicalSci"},{"issue":"1","key":"1727_CR25","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1080\/13696998.2022.2071528","volume":"25","author":"J Tobin","year":"2022","unstructured":"Tobin J, Ford JH, Tockhorn-Heidenreich A, Nichols RM, Ye W, Bhandari R et al (2022) Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials. J Med Econ 25(1):630\u2013639","journal-title":"J Med Econ"},{"issue":"3","key":"1727_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40273-020-00996-2","volume":"39","author":"R Mahon","year":"2021","unstructured":"Mahon R, Lang A, Vo P, Huels J, Cooney P, Danyliv A et al (2021) Cost-effectiveness of Erenumab for the Preventive Treatment of Migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics 39(3):357\u2013372","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"1727_CR27","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","volume":"38","author":"M Sussman","year":"2018","unstructured":"Sussman M, Benner J, Neumann P, Menzin J (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia 38(10):1644\u20131657","journal-title":"Cephalalgia"},{"issue":"7","key":"1727_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/13696998.2018.1457533","volume":"21","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S et al (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ 21(7):666\u2013675","journal-title":"J Med Econ"},{"issue":"2","key":"1727_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Long-term effectiveness of three Anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score. CNS Drugs 36(2):191\u2013202","journal-title":"CNS Drugs"},{"issue":"1","key":"1727_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, Altamura C, d\u2019Onofrio F, Finocchi C et al (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23(1):138","journal-title":"J Headache Pain"},{"issue":"7","key":"1727_CR31","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/ph16070934","volume":"16","author":"J Hong","year":"2023","unstructured":"Hong J, Bin, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U (2023) A scoping review and Meta-analysis of Anti-CGRP monoclonal antibodies: Predicting Response. Pharmaceuticals 16(7):934","journal-title":"Pharmaceuticals"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01727-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01727-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T09:02:28Z","timestamp":1707728548000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01727-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1727"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01727-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Vall d\u2019Hebron Ethics Committee (PR(AG)53\/2017). All patients gave an informed consent for the analysis of anonymous patients\u2019 data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients and their legal tutors consented to publication of anonymous individual data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CLH reports no disclosures. EC has received honoraria from Novartis, Chiesi, Lundbeck, MedScape; his salary has been partially funded by R\u00edo Hortega grant Acci\u00f3n Estrat\u00e9gica en Salud 2017\u20132020, Instituto de Salud Carlos III (CM20\/00217). He is a junior editor for Cephalalgia. JRM reports no disclosures. VJG reports no disclosures. AA has received honoraria from Allergan-AbbVie, Novartis, Chiesi. MTF has received honoraria from Allergan-AbbVie, Novartis, Chiesi and Teva. PPR has received, in the last three years, honoraria as a consultant and speaker for: AbbVie, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis, Pfizer and Teva. Her research group has received research grants from AbbVie, Novartis and Teva; as well as, Instituto Salud Carlos III, EraNet Neuron, European Regional Development Fund (001-P-001682) under the framework of the FEDER Operative Programme for Catalunya 2014-2020 - RIS3CAT; has received funding for clinical trials from AbbVie, Amgen, Biohaven, Eli Lilly, Novartis, Teva. She is the Honorary Secretary of the International Headache Society. She is in the editorial board of Revista de Neurologia. She is an associate editor for Cephalalgia, Headache, Neurologia, The Journal of Headache and Pain and Frontiers of Neurology. She is a member of the Clinical Trials Guidelines Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of www.midolordecabeza.org. PPR does not own stocks from any pharmaceutical company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}